Dr. Jill C. Milne Ph.D. serves as President, Chief Executive Officer, Co-Founder, Director of the Company. Dr. Milne worked as head of discovery biology at Sirtris Pharmaceuticals, a biotechnology company, from 2004 to 2008, when it was acquired by GlaxoSmithKline. From 1998 to 2004, Dr. Milne worked at Pfizer Global Research and Development, where she served as the worldwide head of the Drug Pfinder Program and head of the Enzyme Target Group at the Pfizer Discovery Technology Center in Cambridge, Massachusetts. Prior to joining Pfizer, she was an American Cancer Society postdoctoral fellow in the department of biological chemistry and molecular pharmacology at Harvard Medical School from 1995 to 1998. Dr. Milne holds a Ph.D. from Harvard University and a B.A. in biological chemistry from Wellesley College. Milne is qualified to serve on our Board of Directors because of her extensive leadership experience in the life sciences industry and her extensive knowledge of our company based on her role as co-founder and Chief Executive Officer.
As the President, Chief Executive Officer, Co-Founder a Director of Astria Therapeutics Inc, the total compensation of Jill Milne at Astria Therapeutics Inc is $1,032,800. There are no executives at Astria Therapeutics Inc getting paid more.
Jill Milne is 52, he's been the President, Chief Executive Officer, Co-Founder a Director of Astria Therapeutics Inc since 2019. There are 9 older and 1 younger executives at Astria Therapeutics Inc. The oldest executive at Astria Therapeutics Inc is Michael Kishbauch, 71, who is the Independent Director.
Jill's mailing address filed with the SEC is C/O CATABASIS PHARMACEUTICALS, INC.,, 100 HIGH STREET, FLOOR 28, BOSTON, MA, 02110.
Over the last 9 years, insiders at Astria Therapeutics Inc have traded over $0 worth of Astria Therapeutics Inc stock and bought 3,064,797 units worth $36,777,564 . The most active insiders traders include Jean George, Nicholas Galakatos a Lifesciences Ii, L.P.Clarus.... On average, Astria Therapeutics Inc executives and independent directors trade stock every 0 days with the average trade being worth of $2,617,339. The most recent stock trade was executed by Lifesciences Ii, L.P.Clarus... on 30 June 2015, trading 376,695 units of CATB stock currently worth $4,520,340.
Astria Therapeutics Inc executives and other stock owners filed with the SEC include: